Calamos Advisors LLC Decreases Holdings in Novo Nordisk A/S $NVO

Calamos Advisors LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 37.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 111,232 shares of the company’s stock after selling 65,195 shares during the period. Calamos Advisors LLC’s holdings in Novo Nordisk A/S were worth $5,659,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. True Wealth Design LLC lifted its holdings in Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares during the last quarter. Guerra Advisors Inc purchased a new stake in Novo Nordisk A/S during the 3rd quarter worth about $25,000. WealthCollab LLC lifted its holdings in Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust purchased a new stake in Novo Nordisk A/S during the 4th quarter worth about $28,000. Finally, Maseco LLP purchased a new stake in Novo Nordisk A/S during the 4th quarter worth about $29,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Late‑stage pediatric trial win — oral semaglutide met its main goal in 10–17 year olds with type 2 diabetes, supporting a planned U.S. launch and expanding addressable market for an oral GLP‑1 in youth. Novo Nordisk’s new weight-loss pill meets main goal in late-stage diabetes study
• Positive Sentiment: Market reaction to trial news — outlets report NVO shares rising after the pediatric oral semaglutide data, indicating investor enthusiasm for incremental product launches and revenue growth. Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
• Positive Sentiment: Competitive edge in obesity market — early prescription data show Lilly’s new obesity treatment trailing Novo’s Wegovy, pressuring Lilly shares and reinforcing Novo’s market leadership in weight‑loss drugs. Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy
• Positive Sentiment: Short interest fell sharply — short interest declined ~14.6% in April to ~17.0M shares (0.4% of float), lowering potential short‑squeeze risk and signaling reduced bearish positioning. (internal short‑interest data)
• Neutral Sentiment: Valuation/price discussion — analysts and commentators are parsing whether current pricing reflects recent share weakness and longer‑term growth prospects; this keeps the stock sensitive to further data and guidance. Is Novo Nordisk (NYSE:NVO) Pricing Reflect Its Recent Share Slump And Growth Outlook
• Negative Sentiment: Analyst target trimmed — Citigroup cut its price target (DKK 309 → DKK 275) while keeping a neutral rating, a reminder of lingering valuation concerns that could cap upside. NVO Stock Gets Cut to DKK 275 — Yet The Bigger Story Remains Intact
• Negative Sentiment: Recent short‑term pullbacks — coverage noted a recent session where NVO closed lower, highlighting that momentum can reverse on macro or sector weakness. Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market

Novo Nordisk A/S Stock Up 0.1%

Novo Nordisk A/S stock opened at $41.19 on Monday. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The company has a market capitalization of $183.93 billion, a P/E ratio of 11.87, a PEG ratio of 9.80 and a beta of 0.73. The stock has a 50-day simple moving average of $39.13 and a 200-day simple moving average of $47.65.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Equities research analysts expect that Novo Nordisk A/S will post 3.34 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were paid a dividend of $1.2751 per share. The ex-dividend date of this dividend was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio is currently 50.43%.

Analyst Ratings Changes

NVO has been the subject of a number of recent analyst reports. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday. CICC Research assumed coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price for the company. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Finally, Citigroup assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating for the company. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.